RadNet earnings release, August 10, 2026
RadNet Reports Second Quarter Financial Results with Record Quarterly
Revenue and Adjusted EBITDA
Financial statements
Income Statement
Three Months Ended June 30, — (unaudited) (in thousands)
| Three Months Ended June 30, – 2026 | Three Months Ended June 30, – 2025 | Six Months Ended June 30, – 2026 | Six Months Ended June 30, – 2025 | ||
|---|---|---|---|---|---|
| Service fee revenue | 592,589 | 468,063 | 1,137,807 | 907,412 | |
| Revenue under capitation arrangements | 30,131 | 30,167 | 60,544 | 62,217 | |
| Total service revenue | 622,720 | 498,230 | 1,198,351 | 969,629 | |
| OPERATING EXPENSES | Cost of operations, excluding depreciation and amortization | 534,640 | 429,085 | 1,085,152 | 882,565 |
| OPERATING EXPENSES | Lease abandonment charges | 1,306 | 123 | 1,306 | 5,511 |
| OPERATING EXPENSES | Depreciation and amortization | 45,529 | 35,993 | 90,496 | 71,476 |
| OPERATING EXPENSES | Loss (gain) on sale and disposal of equipment and other | 1,117 | 1,724 | 3,708 | 2,126 |
| OPERATING EXPENSES | Severance costs | 660 | 426 | 2,124 | 1,173 |
| OPERATING EXPENSES | Total operating expenses | 583,252 | 467,351 | 1,182,786 | 962,851 |
| OPERATING EXPENSES | INCOME (LOSS) FROM OPERATIONS | 39,468 | 30,879 | 15,565 | 6,778 |
| OTHER INCOME AND EXPENSES | Interest expense | 18,153 | 17,189 | 35,810 | 34,428 |
| OTHER INCOME AND EXPENSES | Equity in earnings of joint ventures | -4,710 | -4,356 | -8,535 | -6,955 |
| OTHER INCOME AND EXPENSES | Non-cash change in fair value of interest rate hedge | 1,956 | 4,062 | ||
| OTHER INCOME AND EXPENSES | Debt restructuring and extinguishment expenses | 3,368 | 3,368 | ||
| OTHER INCOME AND EXPENSES | Other (income) expenses | -3,960 | -7,764 | -8,867 | -15,476 |
| OTHER INCOME AND EXPENSES | Total other (income) expenses | 12,851 | 7,025 | 21,776 | 16,059 |
| OTHER INCOME AND EXPENSES | INCOME (LOSS) BEFORE INCOME TAXES | 26,617 | 23,854 | -6,211 | -9,281 |
| OTHER INCOME AND EXPENSES | Provision for income taxes | -6,363 | -820 | 1,733 | 2,578 |
| OTHER INCOME AND EXPENSES | NET INCOME (LOSS) | 20,254 | 23,034 | -4,478 | -6,703 |
| OTHER INCOME AND EXPENSES | Net income (loss) attributable to noncontrolling interests | 12,724 | 8,580 | 21,458 | 16,769 |
| OTHER INCOME AND EXPENSES | NET INCOME (LOSS) ATTRIBUTABLE TO RADNET, INC. COMMON STOCKHOLDERS | 7,530 | 14,454 | -25,936 | -23,472 |
| OTHER INCOME AND EXPENSES | BASIC NET INCOME (LOSS) PER SHARE ATTRIBUTABLE TO RADNET, INC. COMMON STOCKHOLDERS | 0.1 | 0.19 | -0.33 | -0.32 |
| OTHER INCOME AND EXPENSES | DILUTED NET INCOME (LOSS) PER SHARE ATTRIBUTABLE TO RADNET, INC. COMMON STOCKHOLDERS | 0.1 | 0.19 | -0.33 | -0.32 |
| WEIGHTED AVERAGE SHARES OUTSTANDING | Basic | 77,788,452 | 74,352,498 | 77,425,061 | 74,070,438 |
| WEIGHTED AVERAGE SHARES OUTSTANDING | Diluted | 78,731,021 | 75,531,743 | 77,425,061 | 74,070,438 |
Income Statement
Three Months Ended June 30, — (IN THOUSANDS) (in thousands)
| Three Months Ended June 30, – 2026 | Three Months Ended June 30, – 2025 | Six Months Ended June 30, – 2026 | Six Months Ended June 30, – 2025 | ||
|---|---|---|---|---|---|
| Net income (loss) attributable to Radnet, Inc. common stockholders | 7,530 | 14,454 | -25,936 | -23,472 | |
| Income taxes | 6,363 | 820 | -1,733 | -2,578 | |
| Interest expense | 18,153 | 17,189 | 35,810 | 34,428 | |
| Severance costs | 660 | 426 | 2,124 | 1,173 | |
| Depreciation and amortization | 45,529 | 35,993 | 90,496 | 71,476 | |
| Non-cash employee stock-based compensation | 10,540 | 8,741 | 41,915 | 37,235 | |
| Loss (gain) on sale and disposal of equipment and other | 1,117 | 1,724 | 3,708 | 2,126 | |
| Non-cash change in fair value of interest rate hedge | 1,956 | 4,062 | |||
| Other expenses (income) | -3,960 | -7,764 | -8,867 | -15,476 | |
| Non-Capitalized R&D - DeepHealth Cloud OS & Generative AI | 5,110 | 4,787 | 9,670 | 8,349 | |
| Lease abandonment charges | 1,306 | 123 | 1,306 | 5,511 | |
| Loss (gain) on extinguishment of debt and related expenses | 3,368 | 3,368 | |||
| Non-cash change to contingent consideration | -3,157 | -393 | |||
| Non-operational rent expenses | 498 | 496 | 1,398 | 1,838 | |
| Acquisition transaction costs | 6,599 | 2,301 | 10,053 | 2,973 | |
| Adjusted EBITDA - Radnet, Inc. | 99,656 | 81,246 | 162,919 | 127,645 | |
| NOTE | Adjusted EBITDA - Imaging Center Segment | 97,178 | 77,843 | 159,138 | 120,531 |
| NOTE | Adjusted EBITDA - Digital Health Segment | 2,478 | 3,403 | 3,781 | 7,114 |
Balance Sheet
June 30, 2026 — (IN THOUSANDS EXCEPT SHARE AND PER SHARE DATA)
| June 30, 2026 – (unaudited) | December 31, 2025 | ||
|---|---|---|---|
| CURRENT ASSETS | Cash and Cash equivalents | 726,272 | 767,215 |
| CURRENT ASSETS | Accounts receivable | 241,845 | 200,317 |
| CURRENT ASSETS | Due from affiliates | 6,863 | 12,592 |
| CURRENT ASSETS | Prepaid expenses and other current assets | 60,776 | 52,003 |
| CURRENT ASSETS | Total current assets | 1,035,756 | 1,032,127 |
| PROPERTY, EQUIPMENT AND RIGHT-OF-USE ASSETS | Property and equipment, net | 879,904 | 807,702 |
| PROPERTY, EQUIPMENT AND RIGHT-OF-USE ASSETS | Operating lease right-of-use assets | 759,225 | 690,250 |
| PROPERTY, EQUIPMENT AND RIGHT-OF-USE ASSETS | Total property, plant, equipment and right-of-use assets | 1,639,129 | 1,497,952 |
| OTHER ASSETS | Goodwill | 1,122,468 | 907,663 |
| OTHER ASSETS | Other intangible assets | 245,348 | 148,508 |
| OTHER ASSETS | Deferred financing costs | 1,393 | 1,684 |
| OTHER ASSETS | Investment in joint ventures | 135,019 | 130,340 |
| OTHER ASSETS | Deposits and other | 47,238 | 40,289 |
| OTHER ASSETS | Total Assets | 4,226,351 | 3,758,563 |
| CURRENT LIABILITIES | Accounts payable, accrued expenses and other | 489,818 | 422,029 |
| CURRENT LIABILITIES | Due to affiliates | 91,298 | 70,104 |
| CURRENT LIABILITIES | Deferred revenue | 16,480 | 7,272 |
| CURRENT LIABILITIES | Current operating lease liability | 69,557 | 61,934 |
| CURRENT LIABILITIES | Current portion of notes payable | 30,669 | 25,424 |
| CURRENT LIABILITIES | Total current liabilities | 697,822 | 586,763 |
| LONG-TERM LIABILITIES | Long-term finance lease liability | 4,288 | |
| LONG-TERM LIABILITIES | Long-term operating lease liability | 776,329 | 707,001 |
| LONG-TERM LIABILITIES | Notes payable, net of current portion | 1,301,862 | 1,064,495 |
| LONG-TERM LIABILITIES | Deferred tax liability, net | 39,005 | 21,903 |
Cash Flow
Original Guidance Range — Digital Health Segment (in millions)
| Original Guidance Range | Revised Guidance Range After Q1 Results | Revised Guidance Range After Q2 Results | |
|---|---|---|---|
| Total Net Revenue (inclusive of intersegment revenue) | $135 - $145 million | $135 - $145 million | $135 - $145 million |
| Adjusted EBITDA(1) Before Non-Capitalized R&D - DeepHealth Cloud OS & Generative AI | $10 - $12 million | $10 - $12 million | $10 - $12 million |
| Non-Capitalized R&D - DeepHealth Cloud OS & Generative AI | $17 - $19 million | $17 - $19 million | $17 - $19 million |
| Capital Expenditures | $9 - $12 million | $9 - $12 million | $9 - $12 million |
| Free Cash Flow(2) Before Non-Capitalized R&D - DeepHealth Cloud OS & Generative AI | $(1) - $3 million | $(1) - $3 million | $(1) - $3 million |
Cash Flow
Six Months Ended June 30, — (unaudited) (in thousands)
| Six Months Ended June 30, – 2026 | Six Months Ended June 30, – 2025 | ||
|---|---|---|---|
| Net loss | -4,478 | -6,703 | |
| Adjustments to reconcile net loss to net cash provided by operating activities: | Depreciation and amortization | 90,496 | 71,476 |
| Adjustments to reconcile net loss to net cash provided by operating activities: | Noncash operating lease expense | 32,658 | 29,356 |
| Adjustments to reconcile net loss to net cash provided by operating activities: | Equity in earnings of joint ventures, net of dividends | -4,679 | -1,267 |
| Adjustments to reconcile net loss to net cash provided by operating activities: | Amortization of deferred financing costs and loan discount | 1,550 | 1,471 |
| Adjustments to reconcile net loss to net cash provided by operating activities: | Loss on sale and disposal of equipment | 3,708 | 2,126 |
| Adjustments to reconcile net loss to net cash provided by operating activities: | Loss on extinguishment of debt | 407 | |
| Adjustments to reconcile net loss to net cash provided by operating activities: | Lease abandonment charges | 1,306 | 5,511 |
| Adjustments to reconcile net loss to net cash provided by operating activities: | Amortization of cash flow hedge | 2,712 | |
| Adjustments to reconcile net loss to net cash provided by operating activities: | Non-cash change in fair value of interest rate swap | 4,062 | |
| Adjustments to reconcile net loss to net cash provided by operating activities: | Stock-based compensation | 41,915 | 37,235 |
| Adjustments to reconcile net loss to net cash provided by operating activities: | Change in fair value of contingent consideration | -393 | |
| Changes in operating assets and liabilities, net of assets acquired and liabilities assumed in purchase transactions: | Accounts receivable | -23,413 | -14,159 |
| Changes in operating assets and liabilities, net of assets acquired and liabilities assumed in purchase transactions: | Other current assets | -1,131 | 22,381 |
| Changes in operating assets and liabilities, net of assets acquired and liabilities assumed in purchase transactions: | Other assets | -7,443 | -2,544 |
| Changes in operating assets and liabilities, net of assets acquired and liabilities assumed in purchase transactions: | Deferred taxes | -3,784 | -3,511 |
| Changes in operating assets and liabilities, net of assets acquired and liabilities assumed in purchase transactions: | Operating leases | -29,238 | -34,726 |
| Changes in operating assets and liabilities, net of assets acquired and liabilities assumed in purchase transactions: | Deferred revenue | 1,016 | 145 |
| Changes in operating assets and liabilities, net of assets acquired and liabilities assumed in purchase transactions: | Accounts payable, accrued expenses and other | 74,574 | 48,264 |
| Changes in operating assets and liabilities, net of assets acquired and liabilities assumed in purchase transactions: | Net cash provided by operating activities | 173,071 | 161,829 |
| CASH FLOWS FROM INVESTING ACTIVITIES | Purchase of imaging facilities and other acquisitions, net of cash acquired | -315,707 | -31,985 |
| CASH FLOWS FROM INVESTING ACTIVITIES | Purchase of property and equipment and other | -126,215 | -101,776 |
| CASH FLOWS FROM INVESTING ACTIVITIES | Proceeds from sale of equipment | 744 | 40 |
| CASH FLOWS FROM INVESTING ACTIVITIES | Equity contributions in existing and purchase of interest in joint ventures | -20,480 | |
| CASH FLOWS FROM INVESTING ACTIVITIES | Collection of notes receivable | 6,651 | |
| CASH FLOWS FROM INVESTING ACTIVITIES | Net cash used in investing activities | -434,527 | -154,201 |
| CASH FLOWS FROM FINANCING ACTIVITIES | Principal payments on notes and leases payable | -11,767 | -3,461 |
| CASH FLOWS FROM FINANCING ACTIVITIES | Payments on Term Loan Debt | -11,140 | -10,252 |
| CASH FLOWS FROM FINANCING ACTIVITIES | Proceeds from issuance of new debt, net of issuing costs | 248,937 | 99,001 |
| CASH FLOWS FROM FINANCING ACTIVITIES | Purchase of noncontrolling interests by third party | 2,389 | |
| CASH FLOWS FROM FINANCING ACTIVITIES | Distributions paid to noncontrolling interests | -3,927 | -3,313 |
| CASH FLOWS FROM FINANCING ACTIVITIES | Proceeds from issuance of common stock upon exercise of options | 612 | 554 |
Full release
(1) and Revises Upwards 2026 Financial Guidance Ranges
LOS ANGELES, California, August 9, 2026 – RadNet, Inc. (NASDAQ: RDNT)
(“RadNet” or the “Company”), a national leader in providing high-quality, cost-effective, fixed-site outpatient diagnostic imaging services through a network of 442 owned and operated outpatient imaging centers, today reported financial results for its second quarter of 2026.
Dr. Howard Berger, President and Chief Executive
Officer of RadNet, commented, “The Imaging Center and Digital Health reportable operating segments continue to demonstrate strong growth and achieve record quarterly results. In the second quarter of 2026, Total Company Revenue grew 25.0% and Digital Health segment
Revenue increased 56.5% from last year’s same quarter. Growth was driven by strong increases in aggregate and same center procedural volumes, the contribution from recent acquisitions, a continuing shift in procedural volumes towards advanced imaging and incremental
Digital Health sales and licenses of Enterprise Imaging and AI solutions.”
Dr. Berger continued, “Within the Imaging
Center operating segment, we continue to have success in driving more advanced imaging procedures and increasing advanced imaging capacity through a variety of operating and Digital Health technology initiatives. Aggregate advanced imaging procedural volumes increased 21.2% and same-center advanced imaging procedural volumes increased 9.6% as compared with the second quarter of 2025. The disproportionally higher growth in MR, CT and PET/CT relative to routine imaging contributed to a 238 basis point shift in RadNet’s advanced imaging procedural volume mix as compared with the same quarter last year, increasing from 27.5% in last year’s second quarter to 29.9% in the second quarter of 2026. This favorable business mix shift contributed to a 16.1% Adjusted EBITDA
(1) margin for the Imaging
Center segment during this year’s second quarter, a 17 basis point improvement as compared with last year’s second quarter.”
“The Digital Health division continues to make significant progress. At June 30, 2026, ARR was $105.5 million, an increase of 97.2% from June 30, 2025 and an increase of 8.9% sequentially from March 31, 2026. ARR generated by external (non- RadNet) customers now comprises approximately 63% of Digital Health Revenue. During the second quarter, we signed new business with Total Contract Value of approximately $21 million, bringing our six-month new business
Total Contract Value to approximately $37 million. The majority of our new business is with hospitals and health systems and spans the full breadth of DeepHealth AI and Enterprise Imaging solutions. On the regulatory front, at the end of July, DeepHealth’s breast ultrasound AI solution was cleared by the FDA. We expect to implement this solution across RadNet’s breast imaging centers by year-end and anticipate both Revenue and cost savings contributions in the second half of this year from the roll-out,” added Dr. Berger.
Dr. Berger continued, “Our joint venture business continues to grow. As of the end of the second quarter, 157 of our 442 locations (or approximately 36%) were held within health system partnerships. During the second quarter, we announced a multi-site joint venture in Boise, Idaho with Trinity Health’s Saint
Alphonsus Health System to initially include the operations of five multimodality outpatient imaging centers. As part of the relationship, our contracted radiology group, Gem State Radiology, and the Saint Alphonsus hospitals in Boise will be adopting a variety of DeepHealth solutions including Diagnostic Suite, Reporting Pro, AI Studio and various clinical AI.”
“Given the positive trends within the industry and RadNet’s strong financial performance of the second quarter, we are revising upwards 2026 Imaging Center guidance levels for
Revenue, Adjusted EBITDA
(1) and Free Cash Flow
(2) in anticipation of financial results that we believe will exceed both our original expectations and the amendments we made to the guidance ranges upon releasing first quarter 2026 results in May,” concluded Dr. Berger.
Second Quarter Financial Results
For the second quarter of 2026, RadNet reported
Total Company Revenue of $622.7 million and Adjusted EBITDA
(1) of $99.7 million. Revenue increased $124.5 million (or 25.0%) and Adjusted EBITDA
(1) increased $18.4 million (or 22.7%) as compared with the second quarter of 2025.
For the second quarter of 2026, RadNet reported
Digital Health Revenue (inclusive of intersegment revenue) of $32.4 million and Adjusted EBITDA
(1) of $2.5 million. Revenue increased $11.7 million (or 56.5%) and Adjusted EBITDA
(1) decreased $0.9 million (or 27.2%) as compared with the second quarter of 2025. The decrease in Digital Health Adjusted EBITDA
(1) resulted predominantly from investments in headcount to fuel growth in sales, marketing, customer service and implementation teams. At June 30, 2026, Annual Recurring Revenue
(4)
(ARR) for Digital
Health was $105.5 million, as compared with $53.5 million as of June 30, 2025.
Unadjusted for unusual or one-time items impacting the second quarter of 2026, Total Company Net Income for the second quarter of 2026 was $7.5 million as compared with a Total Company
Net Income of $14.5 million for the second quarter of 2025. Net Income Per Share for the second quarter of 2026 was $0.10, compared with a Net Income per share of $0.19 in the second quarter of 2025, based upon a weighted average number of diluted shares outstanding of 78.7 million shares in 2026 and 75.5 million shares in 2025.
There were a number of unusual or one-time items... (truncated)lities under construction that have yet to open their operations; $5.1 million of non-capitalized research and development expenses with respect to DeepHealth solutions; $6.8 million of Intangibles amortization within the Digital Health division primarily related recent acquisitions; $1.3 million of lease abandonment charges; $6.6 million of acquisition transaction costs; $3.2 million gain on the change in contingent consideration related to recent acquisitions; and $3.4 million loss from debt restructuring and extinguishment related to our recent debt repricing transaction. Adjusting for the above items, Total Company Adjusted Earnings
(3) was $23.2 million and diluted Adjusted Earnings Per Share
(3) was $0.29 during the second quarter of 2026. This compares with Total Company Adjusted Earnings
(3) of $25.7 million and diluted
Adjusted Earnings Per Share
(3) of $0.34 during the second quarter of 2025.
For the second quarter of 2026, as compared with the prior year’s second quarter, MRI volume increased 21.0%, CT volume increased 20.9%, PET/CT volume increased 31.0% and routine imaging (inclusive of nuclear medicine, ultrasound, mammography, x-ray and other exams) increased 7.9% over the prior year’s second quarter. On a same-center basis, including only those centers which were part of RadNet for both the second quarters of 2026 and 2025,
MRI volume increased 10.2%, CT volume increased 8.6%, PET/CT volume increased 8.8% and routine imaging increased 1.7% over the prior year’s second quarter.
Six Month Financial Results
For the first six months of 2026, RadNet reported
Total Company Revenue of $1,198 million and Adjusted EBITDA
(1) of $162.9 million. Revenue increased $228.7 million (or 23.6%) and Adjusted EBITDA
(1) increased $35.3 million (or 27.6%) as compared with the first six months of 2025.
For the first six months of 2026, RadNet reported
Digital Health Revenue (inclusive of intersegment revenue) of $61.5 million and Adjusted EBITDA
(1) of $3.8 million. Revenue increased $21.6 million (or 54.1%) and Adjusted EBITDA
(1) decreased $3.3 million (or 46.9%) as compared with the first six months of 2025.
Unadjusted for one-time or unusual items, Total
Company Net Loss for the first six months of 2026 was $25.9 million as compared with a Total Company Net Loss of $23.5 million for the first six months of 2025. Net Loss Per Share for the six-month period of 2026 was $(0.33), compared with a Net Loss per share of $(0.32) in the six-month period of 2025, based upon a weighted average number of diluted shares outstanding of 77.4 million shares in 2026 and
74.1 million shares in 2025.
2026 Guidance Update
RadNet updates guidance levels as follows:
Imaging Center Segment
Digital Health Segment
Conference Call for Tomorrow
Dr. Howard Berger, President and Chief Executive
Officer, and Mark Stolper, Executive Vice President and Chief Financial Officer, will host a conference call to discuss its second quarter
2026 results on Monday, August 10th, 2026 at 7:30 a.m. Pacific Time (10:30 a.m. Eastern Time).
Conference Call Details:
Date: Monday, August 10, 2026
Time: 7:30 a.m. Pacific Time (10:30 a.m. Eastern
Time)
Dial In-Number: 844-744-1280
International Dial-In Number: 412-564-6465
It is recommended that participants dial in approximately 5 minutes prior to the start of the call. There will also be simultaneous and archived webcasts available at https://viavid.webcasts.com/starthere.jsp?ei=1770869&tp_key=f4d7c2481f or http://www.radnet.com under the “News” menu section of the website. An archived replay of the call will also be available and can be accessed by dialing 844-512-2921 from the U.S., or 412-317-6671 for international callers, and using the passcode 10210872.
About RadNet, Inc.
RadNet, Inc. is a leading national provider of freestanding, fixed-site diagnostic imaging services in the United States based on the number of locations and annual imaging revenue.
RadNet has a network of owned and operated outpatient imaging centers. RadNet’s markets include Arizona, California, Delaware, Florida,
Idaho, Indiana, Maryland, New Jersey, New York, Texas and Virginia. In addition, RadNet provides radiology information technology and artificial intelligence solutions marketed under the DeepHealth brand, teleradiology professional services and other related products and services to customers in the diagnostic imaging industry. Together with contracted radiologists, and inclusive of full-time and per diem employees and technologists, RadNet has a total of over 11,000 employees. For more information, visit http://www.radnet.com.
Forward Looking Statements
This press release contains “forward-looking statements” within the meaning of the safe harbor provisions of the U.S. Private Securities Litigation Reform Act of 1995. Forward-looking statements are expressions of our current beliefs, expectations and assumptions regarding the future of our business, future plans and strategies, projections, guidance and anticipated future conditions, events and trends. Forward-looking statements can generally be identified by words such as: “anticipate,” “intend,” “plan,” “goal,” “seek,” “believe,”
“project,” “estimate,” “expect,” “strategy,” “future,” “likely,”
“may,” “should,” “will” and similar references to future periods.
Forward-looking statements are neither historical facts nor assurances of future performance. Because forward-looking statements relate to the future, they are inherently subject to uncertainties, risks and changes in circumstances that are difficult to predict and many of which are outside of our control. Our actual results and financial condition may differ materially from those indicated in the forward-looking statements. Therefore, you should not place undue... (truncated)t could cause our actual results and financial condition to differ materially from those indicated in the forward-looking statements include, among others, the following:
The foregoing review of important factors should not be construed as exhaustive and should be read in conjunction with the other cautionary statements that are included elsewhere. Additional information concerning risks, uncertainties and assumptions can be found in RadNet’s filings with the United States Securities and Exchange Commisssion
(the “SEC”), including the risk factors discussed in RadNet’s most recent Annual Report on Form 10-K, as updated by its Quarterly
Reports on Form 10-Q and future filings with the SEC.
Any forward-looking statement contained in this release is based on information currently available to us and speaks only as of the date on which it is made. We undertake no obligation to publicly update any forward-looking statement, whether written or oral, that we may make from time to time, whether as a result of changed circumstances, new information, future developments or otherwise, except as required by applicable law.
Regulation G: GAAP and Non-GAAP Financial
Information
This release contains certain financial information not reported in accordance with GAAP. The Company uses both GAAP and non-GAAP metrics to measure its financial results. The Company believes that, in addition to GAAP metrics, these non-GAAP metrics assist the Company in measuring its cash-based performance. The Company believes this information is useful to investors and other interested parties because it removes unusual and nonrecurring charges that occur in the affected period and provides a basis for measuring the Company’s financial condition against other quarters. Such information should not be considered as a substitute for any measures calculated in accordance with GAAP, and may not be comparable to other similarly titled measures of other companies. Non-GAAP financial measures should not be considered in isolation from, or as a substitute for, financial information prepared in accordance with GAAP. Reconciliation of this information to the most comparable GAAP measures is included in this release in the tables which follow.
CONTACTS:
RadNet, Inc.
Mark Stolper, 310-445-2800
Executive Vice President and Chief Financial
Officer